What Matters Now
CME
Optimizing Treatment Selection in Chronic Lymphocytic Leukemia
0:00 / 0:00
Joshua Brody, MD, Mount Sinai
Graham Wehmeyer, MD, Icahn School of Medicine at Mount Sinai
87% of Peers Changed Their Practice After this Clinical Scenario
CME
Deciding between continuous and fixed-duration CLL treatment balancing patient preference for intervals and clinical considerations.
What Matters Now
CME
0:00 / 0:00
Optimizing Treatment Selection in Chronic Lymphocytic Leukemia
Joshua Brody, MD, Mount Sinai
Graham Wehmeyer, MD, Icahn School of Medicine at Mount Sinai
Corresponding Scenario
More Than One Right Answer - Choosing a Frontline Strategy When Continuous and Fixed-Duration Both Fit
See experiences from 17 peers
Deciding between continuous and fixed-duration CLL treatment balancing patient preference for intervals and clinical considerations.
How clinicians responded after this Clinical Scenario
60
%
begin unsure how to apply evidence
87
%
will implement a practice change
NEW!
Sharpen your clinical judgment for real-world care.
Discover how experts and peers reason
See where small differences in reasoning change safety, feasibility, and escalation decisions.
Reflect on your decision logic
Practice the thinking you used and spot gaps in judgment.
Calibrate your clinical reasoning
Side-by-side, reasoning patterns from peers and experts and how others de-risk their decisions.
Preview
Example: How Your Clinical Reasoning Compares with Peers
This table shows a representative example. Your actual peer comparison is generated after scenario completion.
CME Information
Title: Advancing Confident, Evidence- and Guideline-Aligned Treatment Selection in Chronic Lymphocytic Leukemia
Release Date: July 13, 2026
Expiration Date: July 13, 2027
Estimated Time to Complete: up to 2 hours
Credit: This activity is designated for a maximum of 2.0 AMA PRA Category 1 Credits™. Nurses and physician assistants may claim a maximum of 2.0 contact hours / 2.0 AAPA Category 1 CME credits, and the activity is approved for up to 2.0 ABIM MOC points.
Target Audience: This activity is intended for hematology (MD/DO) and oncology (MD/DO) physicians, nurse practitioners, and physician assistants in these settings, with a focus on clinicians in community-based practice.
Commercial Support: This activity is supported by an independent educational grant from AstraZeneca.
Hematology/Oncology specialists and advanced practice providers managing CLL today are navigating real choices: not just knowing the options, but confidently deciding which path fits this patient, right now. This certified program was built for exactly that challenge. Through expert-led video-based modules and five interactive patient scenarios, you'll sharpen your clinical reasoning across the decisions that matter most: choosing between continuous BTKi-based and fixed-duration strategies when more than one approach makes sense, implementing fixed-duration therapy safely in your practice, and making therapy adjustment decisions in patients receiving frontline CLL treatment. In this CME/CE initiative, you'll see how your peers reason through the same cases, reflect on your own approach, and leave with practical, evidence-aligned frameworks you can apply immediately.
Topics covered:
- Frontline treatment strategy selection
- Fixed-duration therapy implementation (including TLS planning and monitoring)
- Therapy adjustment in frontline CLL treatment
- Patient-centered treatment planning
Get Started
Ready to refine your clinical judgment for everyday practice?
In a short (10 min) interactive scenario, explore how experts and peers reason through uncertainty and apply evidence in real-world care.
87% practice change rate among peers